Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 117-124

  Paller, Channing J ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cabazitaxel; Castration resistant prostate cancer; Clinical trial; Docetaxel resistance; Drug development

Indexed keywords

ABIRATERONE; CABAZITAXEL; CISPLATIN; DOCETAXEL; GEMCITABINE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RPR 116258A; TXD 258; UNCLASSIFIED DRUG; 4 ACETOXY 13 ((3 ((TERT BUTOXYCARBONYL)AMINO) 2 HYDROXY 3 PHENYLPROPANOYL)OXY) 1 HYDROXY 7,10 DIMETHOXY 9 OXO 5,20 EPOXYTAX 11 EN 2 YL BENZOATE; 4-ACETOXY-13-((3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOYL)OXY)-1-HYDROXY-7,10-DIMETHOXY-9-OXO-5,20-EPOXYTAX-11-EN-2-YL BENZOATE; ANTINEOPLASTIC AGENT; TAXOID;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BACKACHE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEST TIGHTNESS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEMATURIA; HUMAN; HYPERSENSITIVITY REACTION; INNER EAR DISEASE; KIDNEY FAILURE; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REFLEX DISORDER; RESPIRATORY FAILURE; REVIEW; SENSORY NEUROPATHY; SEPSIS; SHOCK; SIDE EFFECT; SOLID TUMOR; SUDDEN DEATH; VIBRATION DISEASE; CHEMISTRY; CLINICAL TRIAL (TOPIC); MALE; METASTASIS; ORCHIECTOMY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 79952978362     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S13029     Document Type: Review

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-1597.
3. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010;170(15):1390-1395.
4. Antonarakis ES, Trock BJ, Feng Z, et al. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. J Clin Oncol. 2009;27(Suppl): abstract 5008.
5. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002; 20(23):4567-4573.
6. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756-1764.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
8. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
9. FDA Center for Drug Evaluation and Research. Approval Package for: Jevtana. June 17, 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000Approv.pdf. Accessed February 2, 2011.
10. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-265.
11. Sanofi-Aventis. Jevtana prescribing information. June 17, 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf. Accessed February 2, 2011.
12. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol. 1998; 16(11):3674-3690.
13. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000; 92(16):1295-1302.
14. Rowinsky EK, Smith L, Wang YM, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998;16(9):2964-2976.
15. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723-730.
16. Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp. 2002;243:83-96.
17. Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod. 2009;72(3):507-515.
18. Wilkes G. Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer. Oncology (Williston Park). 2010; 24(10 Suppl):46-48.
19. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxaneresistant metastatic breast cancer patients. Ann Oncol. 2008;19(9): 1547-1552.
20. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147-1154.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
22. De Bono JS, Sartor O. Cabazitaxel for castration-resistant prostate cancer - author's reply. Lancet. 2011;377(9760):122-123.
23. Sartor O, Halstead M, Katz L. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. Clin Genitourin Cancer. 2010;8(1):23-28.
24. Shigeta K, Miura Y, Naito Y, Takano T. Cabazitaxel for castration-resistant prostate cancer. Lancet. 2011;377(9760):121; author reply 122-123.
25. Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging. 2010; 5:395-402.
26. Froehner M, Wirth MP. Cabazitaxel for castration-resistant prostate cancer. Lancet. 2011;377(9760):121-122; author reply 122-123.
27. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5): 411-422.
28. IMS MIDAS. IMS Health. 2010.
29. Manifold C. Cabazitaxel (Jevtana): another arrow in the prostate cancer quiver. Informulary. 2010;3(6):1-2.
30. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a US health insurance plan. J Manag Care Pharm. 2006;12(6):472-478.
31. Baum A. Sanofi-Aventis Sales Model for 2009-2016. In: Paller C, editor. Private correspondence from Morgan Stanley Smith Barney, October 6, 2010 detailing the Sanofi-Aventis Sales Model for 2009-2016, prepared by Andrew Baum, European Pharmaceutical Analyst.
32. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437-1446.
33. De Bono JS, Logothetis CJ, Fizazi K, et al. Abiraterone acetate plus low-dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. 35th ESMO Congress; 2010 Oct 8-12; Milan, Italy. Ann Oncol. 2010;21(Suppl 8):viii.
34. Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(27): 4247-4254.
35. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSAtargeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-1105.